Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.840
+0.140 (8.24%)
At close: Oct 2, 2025, 4:00 PM EDT
1.880
+0.040 (2.17%)
After-hours: Oct 2, 2025, 7:51 PM EDT
Propanc Biopharma Market Cap
Propanc Biopharma has a market cap or net worth of $23.56 million as of October 2, 2025.
Market Cap
23.56M
Enterprise Value
24.13M
1-Year Change
n/a
Ranking
Category
Stock Price
$1.84
Market Cap Chart
Since August 15, 2025, Propanc Biopharma's market cap has decreased from $36.20M to $23.56M, a decrease of -34.90%. That is a compound annual growth rate of -96.68%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Sep 30, 2025 | 21.80M | -6.84% |
Sep 29, 2025 | 23.40M | 1.74% |
Sep 26, 2025 | 23.00M | 0.88% |
Sep 25, 2025 | 22.80M | -6.94% |
Sep 24, 2025 | 24.50M | 2.08% |
Sep 23, 2025 | 24.00M | -6.61% |
Sep 22, 2025 | 25.70M | -5.51% |
Sep 19, 2025 | 27.20M | -1.45% |
Sep 18, 2025 | 27.60M | -1.08% |
Sep 17, 2025 | 27.90M | -0.71% |
Sep 16, 2025 | 28.10M | -1.06% |
Sep 15, 2025 | 28.40M | 1.43% |
Sep 12, 2025 | 28.00M | 12.00% |
Sep 11, 2025 | 25.00M | 14.68% |
Sep 10, 2025 | 21.80M | -7.63% |
Sep 9, 2025 | 23.60M | -4.07% |
Sep 8, 2025 | 24.60M | -9.23% |
Sep 5, 2025 | 27.10M | 8.40% |
Sep 4, 2025 | 25.00M | -21.14% |
Sep 3, 2025 | 31.70M | -7.85% |
Sep 2, 2025 | 34.40M | -9.71% |
Aug 29, 2025 | 38.10M | -3.05% |
Aug 28, 2025 | 39.30M | 5.93% |
Aug 27, 2025 | 37.10M | -2.88% |
Aug 26, 2025 | 38.20M | -10.12% |
View and export this data all the way back to 2025. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 656.78B |
Johnson & Johnson | 440.92B |
AbbVie | 400.85B |
UnitedHealth Group | 311.53B |
Novo Nordisk | 245.50B |
Novartis AG | 240.62B |
Abbott Laboratories | 231.76B |
AstraZeneca | 231.02B |